Presentation is loading. Please wait.

Presentation is loading. Please wait.

SIRTs inhibitor: Sirtinol Supplementary Figure S3A Supplementary Figure S3 Sirtinol but not EX527 or PDF-170 significantly enhances ithe cytotoxic and.

Published byBerenice Price Modified over 9 years ago

Similar presentations

Presentation on theme: "SIRTs inhibitor: Sirtinol Supplementary Figure S3A Supplementary Figure S3 Sirtinol but not EX527 or PDF-170 significantly enhances ithe cytotoxic and."— Presentation transcript:

1 SIRTs inhibitor: Sirtinol Supplementary Figure S3A Supplementary Figure S3 Sirtinol but not EX527 or PDF-170 significantly enhances ithe cytotoxic and cytostatic function of dexamethasone in B-ALL cell lines REH and RS4;11 cells were treated with the a range of concentrations of SIRT inhibitors (0-100μM) and/or dexamethasone. Cell viability analysis was performed after 24, 48 and 72 h using MTT assay. A) Sintinol (SIRT1/2/6 inhibitor); B) EX527 (SIRT1 inhibitor); C) PDF-170 (SIRT2 inhibitor). (t-test: Sirtinol with 1μM dexamethasone verses dexamethasone at 1μM) *significant p<0.05, ** very significant p<0.01 and no marker: not significant.

2 SIRT1 inhibitor: EX-527 Supplementary Figure S3B Supplementary Figure S3 Sirtinol but not EX527 or PDF-170 significantly enhances ithe cytotoxic and cytostatic function of dexamethasone in B-ALL cell lines REH and RS4;11 cells were treated with the a range of concentrations of SIRT inhibitors (0-100μM) and/or dexamethasone. Cell viability analysis was performed after 24, 48 and 72 h using MTT assay. A) Sintinol (SIRT1/2/6 inhibitor); B) EX527 (SIRT1 inhibitor); C) PDF-170 (SIRT2 inhibitor). (t-test: Sirtinol with 1μM dexamethasone verses dexamethasone at 1μM) *significant p<0.05, ** very significant p<0.01 and no marker: not significant.

3 SIRT2 inhibitor: PDF-170 Supplementary Figure S3C Supplementary Figure S3 Sirtinol but not EX527 or PDF-170 significantly enhances ithe cytotoxic and cytostatic function of dexamethasone in B-ALL cell lines REH and RS4;11 cells were treated with the a range of concentrations of SIRT inhibitors (0-100μM) and/or dexamethasone. Cell viability analysis was performed after 24, 48 and 72 h using MTT assay. A) Sintinol (SIRT1/2/6 inhibitor); B) EX527 (SIRT1 inhibitor); C) PDF-170 (SIRT2 inhibitor). (t-test: Sirtinol with 1μM dexamethasone verses dexamethasone at 1μM) *significant p<0.05, ** very significant p<0.01 and no marker: not significant.

Download ppt "SIRTs inhibitor: Sirtinol Supplementary Figure S3A Supplementary Figure S3 Sirtinol but not EX527 or PDF-170 significantly enhances ithe cytotoxic and."

Similar presentations

P

P
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
Tetrandrine(μM): 6 6 6 6 Sorafenib(μM): 0 3 4 5 Tetrandrine(μM): 0 4 5 6 Sorafenib(μM): 4 4 4 4 A B S 1 Cell viability for the combination of sorafenib.

Tetrandrine(μM): Sorafenib(μM): Tetrandrine(μM): Sorafenib(μM): A B S 1 Cell viability for the combination of sorafenib.
Supplemental Figure 1. 1000 cells/ well DLD-1 ALDH+/CD133+ DLD-1 ALDH- /CD133- Supplemental Figure 2.

Supplemental Figure cells/ well DLD-1 ALDH+/CD133+ DLD-1 ALDH- /CD133- Supplemental Figure 2.
Supplemental data Fig. S1 Figure S1 Circulation bilirubin levels in CRC patients and non-tumor patients. Circulation bilirubin levels in CRC patients were.

Supplemental data Fig. S1 Figure S1 Circulation bilirubin levels in CRC patients and non-tumor patients. Circulation bilirubin levels in CRC patients were.
Supplementary Methods TEM (transmission electron microscopy). TEM analysis were performed on EF-TEM LEO 912AB (Carl Zeiss Inc., Germany, Korea Basic Science.

Supplementary Methods TEM (transmission electron microscopy). TEM analysis were performed on EF-TEM LEO 912AB (Carl Zeiss Inc., Germany, Korea Basic Science.
Table S1. Hypoxia increases signaling through JNK in colon cancer cell lines in a cell-specific manner Shown are the ratios of c-Jun phosphorylation during.

Table S1. Hypoxia increases signaling through JNK in colon cancer cell lines in a cell-specific manner Shown are the ratios of c-Jun phosphorylation during.
BA Supplementary Fig. S1. A, quantification of RIP1 expression levels in melanocytic tumors. Data shown are mean immunoreactive score (IRS) ± S.E.M. of.

BA Supplementary Fig. S1. A, quantification of RIP1 expression levels in melanocytic tumors. Data shown are mean immunoreactive score (IRS) ± S.E.M. of.
Tumor necrosis factor-alpha potentiates the cytotoxicity of amiodarone in Hepa1c1c7 cells: roles of caspase activation and oxidative stress Supplementary.

Tumor necrosis factor-alpha potentiates the cytotoxicity of amiodarone in Hepa1c1c7 cells: roles of caspase activation and oxidative stress Supplementary.
10 h5 h 0 h Supplemental Figure 1 14 h 16 h 24 h Untreated Supplemental Figure 1 Untreated cells were analyzed using live cell imaging microscopy. Time.

10 h5 h 0 h Supplemental Figure 1 14 h 16 h 24 h Untreated Supplemental Figure 1 Untreated cells were analyzed using live cell imaging microscopy. Time.
The effects of MRP inhibitors on Cd-induced autophagy, apoptosis, and GSK3αβ phosphorylation in RH460 cells. Cells were pretreated with MK571 (15 µM) and.

The effects of MRP inhibitors on Cd-induced autophagy, apoptosis, and GSK3αβ phosphorylation in RH460 cells. Cells were pretreated with MK571 (15 µM) and.
Supplementary Figure 1A-B A H1299 RH1299 0 15 30 45 60 0 45 80 160 200 LC3-I / II P-GSK-3 (Ser21/9) GSK-3α/β β-actin β-catenine P-GSK-3 (Tyr279/216) B.

Supplementary Figure 1A-B A H1299 RH LC3-I / II P-GSK-3 (Ser21/9) GSK-3α/β β-actin β-catenine P-GSK-3 (Tyr279/216) B.
94Q S 97 66 55Q S 19Q S W1W2 97 66 55Q 19Q TAP eluate 94Q S-1 W2 W1 W2 S-1A. Verification of TAP by Western blot (anti-FLAG). S: supernatant of cell lysate.

94Q S Q S 19Q S W1W Q 19Q TAP eluate 94Q S-1 W2 W1 W2 S-1A. Verification of TAP by Western blot (anti-FLAG). S: supernatant of cell lysate.
Supplementary Data. β-actin IL-13Rα2 65 kDa 42 kDa G26-H2 G26-V2 SnB19-pcDNA SnB19-asIL-13Rα2 Figure S1A.

Supplementary Data. β-actin IL-13Rα2 65 kDa 42 kDa G26-H2 G26-V2 SnB19-pcDNA SnB19-asIL-13Rα2 Figure S1A.
Supplemental Figure 1. Erlotinib does not alter oxygenation of tumors. Tumor pO 2 was measured by phosphorescence lifetime oximetry at times before erlotinib.

Supplemental Figure 1. Erlotinib does not alter oxygenation of tumors. Tumor pO 2 was measured by phosphorescence lifetime oximetry at times before erlotinib.
Supplementary Figure 1 Supplementary Figure 1. Screen for small-molecule compounds modulating luciferase activity. Claudin-4 reporter cells were seeded.

Supplementary Figure 1 Supplementary Figure 1. Screen for small-molecule compounds modulating luciferase activity. Claudin-4 reporter cells were seeded.
Table S1. HTS positive hits.. Figure S1. Isogenic bortezomib (Btz) resistant mouse and human cell models. The indicated human (MM.1S and U266) and mouse.

Table S1. HTS positive hits.. Figure S1. Isogenic bortezomib (Btz) resistant mouse and human cell models. The indicated human (MM.1S and U266) and mouse.
Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.
A B Supplementary Figure 1. (A) Western blots were performed on the three cell lines to analyze the levels of p-ERK, which is a key protein involved in.

A B Supplementary Figure 1. (A) Western blots were performed on the three cell lines to analyze the levels of p-ERK, which is a key protein involved in.
2 4 6 8 10010 1 RLU x10 4 - NBBS [µM] Fig. 1S human GR  no hormone Glucocorticoid 10 -11 M Fig. 1S NBBS does not effect the transactivation mediated by.

RLU x NBBS [µM] Fig. 1S human GR  no hormone Glucocorticoid M Fig. 1S NBBS does not effect the transactivation mediated by.

Similar presentations

Ads by Google